BioCryst Pharmaceuticals, Inc. (BCRX)
NASDAQ: BCRX · Real-Time Price · USD
6.95
-0.07 (-1.00%)
Oct 7, 2025, 4:00 PM EDT - Market closed

BioCryst Pharmaceuticals Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 20202015 - 2019
Period Ending
Oct '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2015 - 2019
1,4591,5581,2272,1402,4921,315
Upgrade
Market Cap Growth
-13.04%26.97%-42.68%-14.12%89.45%147.49%
Upgrade
Enterprise Value
1,9382,0701,6752,4352,6031,253
Upgrade
Last Close Price
6.957.525.9911.4813.857.45
Upgrade
PS Ratio
2.603.463.707.9015.8673.85
Upgrade
PB Ratio
--3.27-2.69-7.26-23.29-68.29
Upgrade
EV/Sales Ratio
3.484.595.058.9916.5670.34
Upgrade
EV/EBITDA Ratio
33.121194.32----
Upgrade
Debt / Equity Ratio
-1.75-1.77-1.86-2.52-5.54-14.51
Upgrade
Debt / EBITDA Ratio
12.17208.58----
Upgrade
Asset Turnover
1.200.900.620.480.340.07
Upgrade
Inventory Turnover
39.3710.117.7112.0018.93-
Upgrade
Quick Ratio
1.982.492.974.505.182.93
Upgrade
Current Ratio
2.252.633.314.895.463.07
Upgrade
Return on Equity (ROE)
------1925.37%
Upgrade
Return on Assets (ROA)
7.46%-0.16%-11.57%-16.30%-24.07%-41.60%
Upgrade
Return on Capital (ROIC)
10.01%-0.21%-14.70%-19.88%-29.76%-55.37%
Upgrade
Earnings Yield
-2.45%-5.71%-18.47%-11.55%-7.39%-13.90%
Upgrade
FCF Yield
1.08%-3.41%-7.93%-7.63%-5.80%-10.31%
Upgrade
Buyback Yield / Dilution
-3.62%-7.54%-3.38%-3.79%-7.08%-44.70%
Upgrade
Updated Aug 4, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q